Saito Shinichi, Takahashi Nagahide, Ishihara Ryoko, Ikeda Masashi, Suzuki Tatsuyo, Kitajima Tsuyoshi, Yamanouchi Yoshio, Iwata Nakao, Yamada Mitsuhiko, Yoshida Keizo, Inada Toshiya, Ozaki Norio
Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Japan.
Neuropsychobiology. 2006;54(4):226-30. doi: 10.1159/000100777. Epub 2007 Mar 15.
Vesicle-associated membrane protein 2 (VAMP2) is a key component of the synaptic vesicle docking/fusion machinery and its mRNA reportedly increases in the frontal cortex of rats following chronic antidepressant and electroconvulsive treatment. VAMP2 is therefore thought to be involved in the mechanism of action of antidepressants and may alter their efficacy. The purpose of this study was to investigate whether the VAMP2 gene is associated with clinical responses to a specific antidepressant, fluvoxamine.
A total of 106 patients with major depressive disorder were given fluvoxamine (50-200 mg/day) for 8 weeks and assessed for severity of depression using the Semi-Structured Interview Guide of the Hamilton Depressive Scale (SIGH-D; 17 items) at 0 and 8 weeks. We defined a clinical response as more than a 50% reduction in baseline SIGH-D within 8 weeks, and defined clinical remission as a SIGH-D score of less than 7 at 8 weeks. Genotyping was performed by PCR-RFLP.
Analysis of haplotype tagging single nucleotide polymorphisms as well as haplotype analysis did not reveal any significant associations.
Our results suggest that the VAMP2 gene is unlikely to play a major role in the efficacy of fluvoxamine.
囊泡相关膜蛋白2（VAMP2）是突触小泡对接/融合机制的关键组成部分，据报道，慢性抗抑郁药和电惊厥治疗后，大鼠额叶皮质中其mRNA水平会升高。因此，VAMP2被认为参与了抗抑郁药的作用机制，并可能改变其疗效。本研究的目的是调查VAMP2基因是否与对特定抗抑郁药氟伏沙明的临床反应相关。
总共106名重度抑郁症患者接受氟伏沙明（50 - 200毫克/天）治疗8周，并在第0周和第8周使用汉密尔顿抑郁量表半结构化访谈指南（SIGH - D；17项）评估抑郁严重程度。我们将临床反应定义为8周内基线SIGH - D降低超过50%，将临床缓解定义为8周时SIGH - D评分低于7分。通过聚合酶链反应 - 限制性片段长度多态性（PCR - RFLP）进行基因分型。
单倍型标签单核苷酸多态性分析以及单倍型分析均未发现任何显著关联。
我们的结果表明，VAMP2基因不太可能在氟伏沙明的疗效中起主要作用。
